Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas.

Aristeidis G Vaiopoulos,Maria Dalamaga,Pelagia Katsimbri,Marios Koumourtzis,Kyriaki Lampadaki,Konstantinos Theodoropoulos,Sofia Theotokoglou,Antonios Kanelleas,Anna Syrmali,Alexandra Filippopoulou,Konstantina Zoupidou,Alexander Katoulis,Evangelia Papadavid

International journal of dermatology（2023）

引用 0|浏览6

暂无评分

摘要

This real-world study confirms the efficacy and safety of guselkumab and risankizumab in psoriatic arthritis and psoriasis reported from clinical trials.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要